Demographic characteristics | Results |
---|---|
Age, mean (range) | 58 (35–87) |
BMI, mean (range) | 24.69 (18.20–30.00) |
Postmenopausal, n (%) | 131 (63.90%) |
Treatment | Â |
Hysterectomy and bilateral salpingooophorectomy | 6 (2.93%) |
Sentinel lymphadenectomy | 25 (12.20%) |
Pelvic lymphadenectomy | 131 (63.90%) |
Para-aortic lymphadenectomy | 39 (19.02%) |
diagnostic curettage | 4 (4.88%) |
Surgical approach | Â |
Open surgery | 16 (7.80%) |
Minimally invasive surgery | 185 (90.24%) |
Laparoscopy | 151 (73.66%) |
Robotic | 34 (16.59%) |
Adjuvant therapy | 104 (50.73%) |
Radiotherapy | 104 (50.73%) |
Chemotherapy | 84 (40.98%) |
Hormonal | 12 (5.85%) |
2009 FIGO stage, n (%) | Â |
Stage IA | 102 (49.75%) |
Stage IB | 21 (10.24%) |
Stage II | 13 (6.34%) |
Stage IIIA | 9 (4.39%) |
Stage IIIB | 7 (3.41%) |
Stage IIIC1 | 36 (17.56%) |
Stage IIIC2 | 7 (3.41%) |
Stage IVA | 6 (2.93%) |
Stage IVB | 4 (1.95%) |
2009- (convert to) 2023 FIGO | Â |
IA-IA1 | 48 |
IA-IA2 | 42 |
IA-IC | 2 |
IA-IIB | 3 |
IA-IIC | 6 |
IB-IB | 10 |
IB-IIC | 11 |
II-IIA | 10 |
II-IIB | 1 |
II-IIC | 3 |
IIIA-IIIA1 | 8 |
IIIA-IIIA2 | 1 |
IIIB-IIIB1 | 7 |
IIIB-IIIB2 | 1 |
IIIC1-IIIC1i | 32 |
IIIC1-IIIC1ii | 4 |
IIIC2-IIIC2i | 6 |
IIIC2-IIIC2ii | 1 |
IVA-IVA | 6 |
IVB-IVB | 4 |
Mean follow-up period | Â |
Progression | 23(11.22%) |
Follow-up Metastatic Site | Â |
Bladder mucosa | 4 |
Bowel mucosa | 3 |
Pelvic Lymph nodes | 2 |
Para-aortic lymph nodes | 3 |
Liver | 1 |
Lung | 7 |
Bone | 3 |
Histologic subtype, n (%) | Â |
Endometrioid | 172 (88.78%) |
Non-endometrioid | 23 (11.22%) |
serous | 15 (7.32%) |
clear cell carcinoma | 8 (3.90%) |
Histologic grade, n (%) | Â |
Grade 1 | 90 (43.90%) |
Grade 2 | 52 (25.37%) |
Grade 3 | 63 (30.73%) |
LVSI | 75 (36.59%) |
Myometrial invasion, n (%) | Â |
< 50% | 61 (29.76%) |
≥ 50% | 69 (33.66%) |
Cervical stroma invasion, n (%) | Â |
No | 177 (86.34%) |
Yes | 26 (12.68%) |
Pelvic Lymph node metastases, n (%) | Â |
No | 66 (50.38%) |
Yes | 65 (49.62%) |
Paraaortic lymph node metastases, n (%) | |
No | 32 (82.05%) |
Yes | 7 (17.95%) |